You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameProgesterone
Accession NumberDB00396  (APRD00700)
TypeSmall Molecule
GroupsApproved, Vet Approved
DescriptionThe major progestational steroid that is secreted primarily by the corpus luteum and the placenta. Progesterone acts on the uterus, the mammary glands, and the brain. It is required in embryo implantation, pregnancy maintenance, and the development of mammary tissue for milk production. Progesterone, converted from pregnenolone, also serves as an intermediate in the biosynthesis of gonadal steroid hormones and adrenal corticosteroids. [PubChem]
Structure
Thumb
Synonyms
(S)-4-Pregnene-3,20-dione
(S)-Pregn-4-en-3,20-dione
(S)-Progesterone
17alpha-Progesterone
17α-progesterone
4-Pregnene-3,20-dione
Agolutin
Akrolutin
Corpus Luteum Hormone
Crinone
delta(4)-Pregnene-3,20-dione
Gelbkoerperhormon
Luteohormone
Lutogynon
Pregn-4-ene-3,20-dione
Progesteron
Progesterona
Progestérone
Progesterone
Progesteronum
External Identifiers
  • BP 14
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Act Progesterone InjectionSolution50 mgIntramuscularActavis Pharma Company2016-04-13Not applicableCanada
CrinoneGel8 %VaginalEmd Serono A Division Of Emd Inc Canada2000-05-20Not applicableCanada
CrinoneGel45 mg/1.125gVaginalActavis Pharma, Inc.1997-05-13Not applicableUs
CrinoneGel90 mg/1.125gVaginalActavis Pharma, Inc.1997-05-13Not applicableUs
CrinoneGel90 mg/1.125gVaginalColumbia Laboratories, Inc.1997-05-13Not applicableUs
CrinoneGel45 mg/1.125gVaginalActavis Pharma, Inc.1997-05-13Not applicableUs
CrinoneGel45 mg/1.125gVaginalColumbia Laboratories, Inc.1997-05-13Not applicableUs
CrinoneGel90 mg/1.125gVaginalActavis Pharma, Inc.1997-05-13Not applicableUs
CrinoneGel90 mg/1.125gVaginalColumbia Laboratories, Inc.1997-05-13Not applicableUs
EndometrinInsert100 mgVaginalFerring Inc2009-11-30Not applicableCanada
EndometrinInsert100 mg/1VaginalFerring Pharmaceuticals Inc.2007-06-21Not applicableUs
Gesterol In Oil-liq Im 50mg/mlLiquid50 mgIntramuscularGermiphene Corporation1995-12-311999-04-14Canada
PMS-progesterone Inj 50mg/ml USPLiquid50 mgIntramuscularPharmascience Inc1989-12-312004-01-21Canada
ProchieveGel90 mg/1.125gVaginalColumbia Laboratories1997-05-13Not applicableUs
ProchieveGel45 mg/1.125gVaginalColumbia Laboratories1997-05-13Not applicableUs
ProgesteroneCapsule200 mg/1OralPd Rx Pharmaceuticals, Inc.2010-07-30Not applicableUs
ProgesteroneCapsule200 mg/1OralWatson Laboratories, Inc.2010-07-30Not applicableUs
ProgesteroneCapsule100 mg/1OralVirtus Pharmaceuticals2016-07-13Not applicableUs
ProgesteroneInjection, solution50 mg/mLIntramuscularActavis Pharma, Inc.1978-05-11Not applicableUs
ProgesteroneCapsule200 mg/1OralVirtus Pharmaceuticals2016-07-13Not applicableUs
ProgesteroneCapsule100 mg/1OralWatson Laboratories, Inc.2010-07-30Not applicableUs
Progesterone Inj 50mg/ml USPLiquid50 mgIntramuscularCytex Pharmaceuticals Inc1992-12-31Not applicableCanada
PrometriumCapsule200 mg/1OralVirtus Pharmaceuticals2016-07-15Not applicableUs
PrometriumCapsule100 mg/1OralAbb Vie Inc.2010-07-30Not applicableUs
PrometriumCapsule200 mg/1OralAbb Vie Inc.2010-07-30Not applicableUs
PrometriumCapsule200 mg/1Oralbryant ranch prepack2010-07-30Not applicableUs
PrometriumCapsule200 mg/1OralPhysicians Total Care, Inc.2004-11-03Not applicableUs
PrometriumCapsule100 mg/1Oralbryant ranch prepack2010-07-30Not applicableUs
PrometriumCapsule100 mgOralMerck Canada Inc1995-12-31Not applicableCanada
PrometriumCapsule100 mg/1OralPhysicians Total Care, Inc.2003-03-14Not applicableUs
PrometriumCapsule100 mg/1OralAvera Mc Kennan Hospital2015-08-11Not applicableUs
PrometriumCapsule100 mg/1OralVirtus Pharmaceuticals2016-07-15Not applicableUs
Teva-progesteroneCapsule100 mgOralTeva Canada Limited2015-04-16Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
ProgesteroneCapsule100 mg/1OralAv Kare, Inc.2014-09-29Not applicableUs
ProgesteroneInjection50 mg/1IntramuscularWest ward Pharmaceutical Corp2010-10-28Not applicableUs
ProgesteroneCapsule200 mg/1OralAv Kare, Inc.2013-06-042015-12-29Us
ProgesteroneInjection, solution50 mg/mLIntramuscularFresenius Kabi USA, LLC2001-07-19Not applicableUs
ProgesteroneCapsule100 mg/1OralAkorn, Inc.2012-10-04Not applicableUs
ProgesteroneCapsule200 mg/1OralBionpharma Inc.2016-09-20Not applicableUs
ProgesteroneCapsule200 mg/1OralAv Kare, Inc.2014-09-29Not applicableUs
ProgesteroneCapsule, liquid filled100 mg/1OralTeva Pharmaceuticals Usa, Inc.2012-03-01Not applicableUs
ProgesteroneInjection, solution50 mg/mLIntramuscularAmerican Regent, Inc.2010-09-29Not applicableUs
ProgesteroneCapsule100 mg/1OralBanner Life Sciences Llc.2015-10-01Not applicableUs
ProgesteroneCapsule200 mg/1OralAkorn, Inc.2012-10-04Not applicableUs
ProgesteroneCapsule100 mg/1OralA S Medication Solutions2014-01-01Not applicableUs
ProgesteroneCapsule100 mg/1OralGolden State Medical Supply, Inc.2014-04-23Not applicableUs
ProgesteroneCapsule, liquid filled200 mg/1OralTeva Pharmaceuticals Usa, Inc.2012-03-01Not applicableUs
ProgesteroneCapsule100 mg/1OralBanner Pharmacaps2014-01-01Not applicableUs
ProgesteroneCapsule200 mg/1OralBanner Life Sciences Llc.2015-10-01Not applicableUs
ProgesteroneCapsule100 mg/1OralA S Medication Solutions2015-10-01Not applicableUs
ProgesteroneCapsule200 mg/1OralGolden State Medical Supply, Inc.2014-04-23Not applicableUs
ProgesteroneCapsule100 mg/1OralBionpharma Inc.2016-09-20Not applicableUs
ProgesteroneCapsule200 mg/1OralBanner Pharmacaps2014-01-01Not applicableUs
ProgesteroneCapsule100 mg/1OralAv Kare, Inc.2013-06-042015-12-29Us
Progesterone Injection USPInjection, solution50 mg/mLIntramuscularPharma Force, Inc.2009-09-04Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
AgolutinBiotika
CyclogestActavis
GesterolNot Available
GestoneNordic Pharma
ProgestasertNot Available
ProgestogelBesins
Qi NingAisheng Pharmaceutical
RelantanAversi
SustenSun Pharma
UtrogestanBesins
UtrogestranFaran Laboratories
UtrovinBestochem
VasclorVerisfield
Brand mixtures
NameLabellerIngredients
Estrogel PropakMerck Canada Inc
SaltsNot Available
Categories
UNII4G7DS2Q64Y
CAS number57-83-0
WeightAverage: 314.4617
Monoisotopic: 314.224580204
Chemical FormulaC21H30O2
InChI KeyRJKFOVLPORLFTN-LEKSSAKUSA-N
InChI
InChI=1S/C21H30O2/c1-13(22)17-6-7-18-16-5-4-14-12-15(23)8-10-20(14,2)19(16)9-11-21(17,18)3/h12,16-19H,4-11H2,1-3H3/t16-,17+,18-,19-,20-,21+/m0/s1
IUPAC Name
(1S,2R,10S,11S,14S,15S)-14-acetyl-2,15-dimethyltetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadec-6-en-5-one
SMILES
[H][C@@]12CC[[email protected]](C(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C
Pharmacology
IndicationFor progesterone supplementation or replacement as part of an Assisted Reproductive Technology (ART) treatment for infertile women with progesterone deficiency and for the treatment of secondary amenorrhea. Also used for the reduction of the incidence of endometrial hyperplasia and the attendant risk of endometrial carcinoma in postmenopausal women receiving estrogen replacement therapy, as well as treatment of abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology such as fibroids or uterine cancer.
Structured Indications
PharmacodynamicsProgesterone is a naturally occuring progestin or a synthetic form of the naturally occurring female sex hormone, progesterone. In a woman's normal menstrual cycle, an egg matures and is released from the ovaries (ovulation). The ovary then produces progesterone, preventing the release of further eggs and priming the lining of the womb for a possible pregnancy. If pregnancy occurs, progesterone levels in the body remain high, maintaining the womb lining. If pregnancy does not occur, progesterone levels in the body fall, resulting in a menstrual period. Progesterone tricks the body processes into thinking that ovulation has already occurred by maintaining high levels of the synthetic progesterone. This prevents the release of eggs from the ovaries.
Mechanism of actionProgesterone shares the pharmacological actions of the progestins. Progesterone binds to the progesterone and estrogen receptors. Target cells include the female reproductive tract, the mammary gland, the hypothalamus, and the pituitary. Once bound to the receptor, progestins like Progesterone will slow the frequency of release of gonadotropin releasing hormone (GnRH) from the hypothalamus and blunt the pre-ovulatory LH (luteinizing hormone) surge. In women who have adequate endogenous estrogen, progesterone transforms a proliferative endometrium into a secretory one. Progesterone is essential for the development of decidual tissue and is necessary to increase endometrial receptivity for implantation of an embryo. Once an embryo has been implanted, progesterone acts to maintain the pregnancy. Progesterone also stimulates the growth of mammary alveolar tissue and relaxes uterine smooth muscle. It has little estrogenic and androgenic activity.
TargetKindPharmacological actionActionsOrganismUniProt ID
Progesterone receptorProteinyes
agonist
HumanP06401 details
Estrogen receptorProteinyes
agonist
HumanP03372 details
Mineralocorticoid receptorProteinyes
antagonist
HumanP08235 details
Steroid 17-alpha-hydroxylase/17,20 lyaseProteinunknown
inhibitor
HumanP05093 details
Kappa-type opioid receptorProteinunknown
activator
HumanP41145 details
Related Articles
AbsorptionProgesterone absorption is prolonged with an absorption half-life of approximately 25-50 hours.
Volume of distributionNot Available
Protein binding96%-99%
Metabolism

Progesterone is metabolized primarily by the liver largely to pregnanediols and pregnanolones.

SubstrateEnzymesProduct
Progesterone
6β-HydroxyprogesteroneDetails
Progesterone
2β-HydroxyprogesteroneDetails
Progesterone
21-HydroxyprogesteroneDetails
Progesterone
17β-HydroxyprogesteroneDetails
17β-Hydroxyprogesterone
17β,21-HydroxyprogesteroneDetails
Progesterone
16β-HydroxyprogesteroneDetails
Progesterone
16β-HydroxyprogesteroneDetails
Progesterone
Not Available
15β-HydroxyprogesteroneDetails
Progesterone
Not Available
7β-HydroxyprogesteroneDetails
Route of eliminationThe glucuronide and sulfate conjugates of pregnanediol and pregnanolone are excreted in the urine and bile. Progesterone metabolites which are excreted in the bile may undergo enterohepatic recycling or may be excreted in the feces. Progesterone metabolites are excreted mainly by the kidneys.
Half life34.8-55.13 hours
Clearance
  • 2510 +/- 135 L/day [cycling women]
ToxicityNot Available
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
17-alpha-hydroxylase deficiency (CYP17)DiseaseSMP00566
Corticosterone methyl oxidase I deficiency (CMO I)DiseaseSMP00577
SteroidogenesisMetabolicSMP00130
Adrenal Hyperplasia Type 3 or Congenital Adrenal Hyperplasia due to 21-hydroxylase DeficiencyDiseaseSMP00373
Congenital Lipoid Adrenal Hyperplasia (CLAH) or Lipoid CAHDiseaseSMP00371
Adrenal Hyperplasia Type 5 or Congenital Adrenal Hyperplasia due to 17 Alpha-hydroxylase DeficiencyDiseaseSMP00372
11-beta-hydroxylase deficiency (CYP11B1)DiseaseSMP00575
Corticosterone methyl oxidase II deficiency - CMO IIDiseaseSMP00578
21-hydroxylase deficiency (CYP21)DiseaseSMP00576
Apparent mineralocorticoid excess syndromeDiseaseSMP00717
3-Beta-Hydroxysteroid Dehydrogenase DeficiencyDiseaseSMP00718
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
2-HYDROXY-1,4-NAPHTHOQUINONEThe therapeutic efficacy of Progesterone can be decreased when used in combination with 2-HYDROXY-1,4-NAPHTHOQUINONE.Experimental
2-mercaptobenzothiazoleThe therapeutic efficacy of Progesterone can be decreased when used in combination with 2-mercaptobenzothiazole.Vet Approved
AbciximabThe therapeutic efficacy of Abciximab can be decreased when used in combination with Progesterone.Approved
AbirateroneThe serum concentration of Progesterone can be increased when it is combined with Abiraterone.Approved
AcarboseThe therapeutic efficacy of Acarbose can be decreased when used in combination with Progesterone.Approved, Investigational
AcebutololThe serum concentration of Acebutolol can be decreased when it is combined with Progesterone.Approved
AcenocoumarolThe therapeutic efficacy of Acenocoumarol can be decreased when used in combination with Progesterone.Approved
AcetaminophenThe serum concentration of Acetaminophen can be decreased when it is combined with Progesterone.Approved
AcetohexamideThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Progesterone.Withdrawn
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be decreased when it is combined with Progesterone.Approved, Vet Approved
AfatinibThe serum concentration of Afatinib can be decreased when it is combined with Progesterone.Approved
AicarThe therapeutic efficacy of Aicar can be decreased when used in combination with Progesterone.Experimental
AlbendazoleThe serum concentration of Progesterone can be increased when it is combined with Albendazole.Approved, Vet Approved
AldosteroneThe serum concentration of Aldosterone can be decreased when it is combined with Progesterone.Experimental
AlectinibThe serum concentration of Progesterone can be increased when it is combined with Alectinib.Approved
AlfentanilThe serum concentration of Progesterone can be increased when it is combined with Alfentanil.Approved, Illicit
AlitretinoinThe serum concentration of Alitretinoin can be decreased when it is combined with Progesterone.Approved, Investigational
AlogliptinThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Progesterone.Approved
AmantadineThe serum concentration of Progesterone can be increased when it is combined with Amantadine.Approved
AmbrisentanThe serum concentration of Ambrisentan can be decreased when it is combined with Progesterone.Approved, Investigational
Aminohippuric acidThe serum concentration of Progesterone can be increased when it is combined with Aminohippuric acid.Approved
AmiodaroneThe metabolism of Progesterone can be decreased when combined with Amiodarone.Approved, Investigational
AmitriptylineThe serum concentration of Amitriptyline can be decreased when it is combined with Progesterone.Approved
AmlodipineThe serum concentration of Progesterone can be increased when it is combined with Amlodipine.Approved
AmorolfineThe therapeutic efficacy of Progesterone can be decreased when used in combination with Amorolfine.Approved
Amphotericin BThe therapeutic efficacy of Progesterone can be decreased when used in combination with Amphotericin B.Approved, Investigational
AmprenavirThe serum concentration of Progesterone can be decreased when it is combined with Amprenavir.Approved
AmsacrineThe serum concentration of Progesterone can be increased when it is combined with Amsacrine.Approved
AN2690The therapeutic efficacy of Progesterone can be decreased when used in combination with AN2690.Investigational
AncrodThe therapeutic efficacy of Ancrod can be decreased when used in combination with Progesterone.Investigational
AnidulafunginThe therapeutic efficacy of Progesterone can be decreased when used in combination with Anidulafungin.Approved, Investigational
Antithrombin III humanThe therapeutic efficacy of Antithrombin III human can be decreased when used in combination with Progesterone.Approved
ApixabanThe therapeutic efficacy of Apixaban can be decreased when used in combination with Progesterone.Approved
AprepitantThe serum concentration of Progesterone can be increased when it is combined with Aprepitant.Approved, Investigational
ArdeparinThe therapeutic efficacy of Ardeparin can be decreased when used in combination with Progesterone.Approved, Withdrawn
ArgatrobanThe therapeutic efficacy of Argatroban can be decreased when used in combination with Progesterone.Approved, Investigational
AripiprazoleThe serum concentration of Aripiprazole can be decreased when it is combined with Progesterone.Approved, Investigational
ArmodafinilThe metabolism of Progesterone can be decreased when combined with Armodafinil.Approved, Investigational
Arsenic trioxideThe serum concentration of Arsenic trioxide can be decreased when it is combined with Progesterone.Approved, Investigational
ArtemetherThe therapeutic efficacy of Progesterone can be decreased when used in combination with Artemether.Approved
AstemizoleThe serum concentration of Progesterone can be increased when it is combined with Astemizole.Approved, Withdrawn
AtazanavirThe metabolism of Progesterone can be decreased when combined with Atazanavir.Approved, Investigational
AtenololThe serum concentration of Atenolol can be decreased when it is combined with Progesterone.Approved
AtomoxetineThe metabolism of Progesterone can be decreased when combined with Atomoxetine.Approved
AtorvastatinThe serum concentration of Progesterone can be increased when it is combined with Atorvastatin.Approved
AxitinibThe serum concentration of Axitinib can be decreased when it is combined with Progesterone.Approved, Investigational
AzelastineThe serum concentration of Progesterone can be increased when it is combined with Azelastine.Approved
AzithromycinThe serum concentration of Progesterone can be increased when it is combined with Azithromycin.Approved
Bafilomycin A1The therapeutic efficacy of Progesterone can be decreased when used in combination with Bafilomycin A1.Experimental
BalaglitazoneThe therapeutic efficacy of Balaglitazone can be decreased when used in combination with Progesterone.Investigational
BecaplerminThe therapeutic efficacy of Becaplermin can be decreased when used in combination with Progesterone.Approved, Investigational
BenzocaineThe serum concentration of Progesterone can be increased when it is combined with Benzocaine.Approved
Benzoic AcidThe therapeutic efficacy of Progesterone can be decreased when used in combination with Benzoic Acid.Approved
BepridilThe serum concentration of Progesterone can be increased when it is combined with Bepridil.Approved, Withdrawn
BetamethasoneThe serum concentration of Betamethasone can be decreased when it is combined with Progesterone.Approved, Vet Approved
BetaxololThe metabolism of Progesterone can be decreased when combined with Betaxolol.Approved
BexaroteneThe serum concentration of Progesterone can be decreased when it is combined with Bexarotene.Approved, Investigational
BifonazoleThe therapeutic efficacy of Progesterone can be decreased when used in combination with Bifonazole.Approved
BiperidenThe serum concentration of Progesterone can be increased when it is combined with Biperiden.Approved
BivalirudinThe therapeutic efficacy of Bivalirudin can be decreased when used in combination with Progesterone.Approved, Investigational
BoceprevirThe metabolism of Progesterone can be decreased when combined with Boceprevir.Approved
BortezomibThe metabolism of Progesterone can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Progesterone can be decreased when it is combined with Bosentan.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Progesterone.Approved
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be decreased when it is combined with Progesterone.Approved
BromocriptineThe serum concentration of Bromocriptine can be decreased when it is combined with Progesterone.Approved, Investigational
BuforminThe therapeutic efficacy of Buformin can be decreased when used in combination with Progesterone.Withdrawn
BuprenorphineThe serum concentration of Progesterone can be increased when it is combined with Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BupropionThe metabolism of Progesterone can be decreased when combined with Bupropion.Approved
BuspironeThe serum concentration of Progesterone can be increased when it is combined with Buspirone.Approved, Investigational
ButenafineThe therapeutic efficacy of Progesterone can be decreased when used in combination with Butenafine.Approved
ButoconazoleThe therapeutic efficacy of Progesterone can be decreased when used in combination with Butoconazole.Approved
C1 Esterase Inhibitor (Human)Progesterone may increase the thrombogenic activities of C1 Esterase Inhibitor (Human).Approved
C1 Esterase Inhibitor (Recombinant)Progesterone may increase the thrombogenic activities of C1 Esterase Inhibitor (Recombinant).Approved
CabazitaxelThe serum concentration of Cabazitaxel can be decreased when it is combined with Progesterone.Approved
CaffeineThe serum concentration of Caffeine can be decreased when it is combined with Progesterone.Approved
CamptothecinThe serum concentration of Camptothecin can be decreased when it is combined with Progesterone.Experimental
CanagliflozinThe serum concentration of Canagliflozin can be decreased when it is combined with Progesterone.Approved
CandesartanThe serum concentration of Progesterone can be increased when it is combined with Candesartan.Approved
CandicidinThe therapeutic efficacy of Progesterone can be decreased when used in combination with Candicidin.Withdrawn
CapecitabineThe metabolism of Progesterone can be decreased when combined with Capecitabine.Approved, Investigational
CaptoprilThe serum concentration of Progesterone can be increased when it is combined with Captopril.Approved
CarbamazepineThe metabolism of Progesterone can be increased when combined with Carbamazepine.Approved, Investigational
CarfilzomibThe serum concentration of Carfilzomib can be decreased when it is combined with Progesterone.Approved
CarvedilolThe serum concentration of Progesterone can be increased when it is combined with Carvedilol.Approved, Investigational
CaspofunginThe therapeutic efficacy of Progesterone can be decreased when used in combination with Caspofungin.Approved
CastanospermineThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Progesterone.Experimental
CelecoxibThe metabolism of Progesterone can be decreased when combined with Celecoxib.Approved, Investigational
CeritinibThe serum concentration of Progesterone can be increased when it is combined with Ceritinib.Approved
CerivastatinThe serum concentration of Cerivastatin can be decreased when it is combined with Progesterone.Withdrawn
CertoparinThe therapeutic efficacy of Certoparin can be decreased when used in combination with Progesterone.Approved
CeruleninThe therapeutic efficacy of Progesterone can be decreased when used in combination with Cerulenin.Approved
ChloramphenicolThe metabolism of Progesterone can be decreased when combined with Chloramphenicol.Approved, Vet Approved
ChloroquineThe serum concentration of Progesterone can be increased when it is combined with Chloroquine.Approved, Vet Approved
ChloroxineThe therapeutic efficacy of Progesterone can be decreased when used in combination with Chloroxine.Approved
ChlorpromazineThe serum concentration of Chlorpromazine can be decreased when it is combined with Progesterone.Approved, Vet Approved
ChlorpropamideThe serum concentration of Progesterone can be increased when it is combined with Chlorpropamide.Approved
ChlorprothixeneThe serum concentration of Progesterone can be increased when it is combined with Chlorprothixene.Approved, Withdrawn
CholecalciferolThe metabolism of Progesterone can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CholesterolThe serum concentration of Progesterone can be increased when it is combined with Cholesterol.Experimental
Cholic AcidProgesterone may decrease the excretion rate of Cholic Acid which could result in a higher serum level.Approved
CiclopiroxThe therapeutic efficacy of Progesterone can be decreased when used in combination with Ciclopirox.Approved, Investigational
CiglitazoneThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Progesterone.Experimental
CilazaprilThe serum concentration of Progesterone can be increased when it is combined with Cilazapril.Approved
CilostazolThe serum concentration of Cilostazol can be increased when it is combined with Progesterone.Approved
CimetidineThe serum concentration of Cimetidine can be decreased when it is combined with Progesterone.Approved
CinacalcetThe metabolism of Progesterone can be decreased when combined with Cinacalcet.Approved
CiprofloxacinThe serum concentration of Ciprofloxacin can be decreased when it is combined with Progesterone.Approved, Investigational
CisplatinThe serum concentration of Cisplatin can be decreased when it is combined with Progesterone.Approved
CitalopramThe serum concentration of Citalopram can be decreased when it is combined with Progesterone.Approved
Citric AcidThe therapeutic efficacy of Citric Acid can be decreased when used in combination with Progesterone.Nutraceutical, Vet Approved
ClarithromycinThe metabolism of Progesterone can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Progesterone can be decreased when combined with Clemastine.Approved
ClobazamThe serum concentration of Clobazam can be decreased when it is combined with Progesterone.Approved, Illicit
ClofazimineThe serum concentration of Progesterone can be increased when it is combined with Clofazimine.Approved, Investigational
ClomifeneThe serum concentration of Clomifene can be decreased when it is combined with Progesterone.Approved, Investigational
ClomipramineThe serum concentration of Progesterone can be increased when it is combined with Clomipramine.Approved, Vet Approved
ClonidineThe serum concentration of Clonidine can be decreased when it is combined with Progesterone.Approved
ClopidogrelThe metabolism of Progesterone can be decreased when combined with Clopidogrel.Approved, Nutraceutical
ClotrimazoleThe therapeutic efficacy of Progesterone can be decreased when used in combination with Clotrimazole.Approved, Vet Approved
ClozapineThe serum concentration of Clozapine can be decreased when it is combined with Progesterone.Approved
CobicistatThe serum concentration of Progesterone can be increased when it is combined with Cobicistat.Approved
CobimetinibThe serum concentration of Cobimetinib can be decreased when it is combined with Progesterone.Approved
CocaineThe metabolism of Progesterone can be decreased when combined with Cocaine.Approved, Illicit
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Progesterone.Approved
ColforsinThe serum concentration of Progesterone can be increased when it is combined with Colforsin.Experimental
ConivaptanThe serum concentration of Progesterone can be increased when it is combined with Conivaptan.Approved, Investigational
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be decreased when it is combined with Progesterone.Approved
CordycepinThe therapeutic efficacy of Progesterone can be decreased when used in combination with Cordycepin.Investigational
CrizotinibThe metabolism of Progesterone can be decreased when combined with Crizotinib.Approved
CyclophosphamideThe serum concentration of Progesterone can be increased when it is combined with Cyclophosphamide.Approved, Investigational
CyclosporineThe therapeutic efficacy of Progesterone can be decreased when used in combination with Cyclosporine.Approved, Investigational, Vet Approved
Cyproterone acetateThe serum concentration of Progesterone can be decreased when it is combined with Cyproterone acetate.Approved, Investigational
Dabigatran etexilateThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Progesterone.Approved
DabrafenibThe serum concentration of Progesterone can be decreased when it is combined with Dabrafenib.Approved
DaclatasvirThe serum concentration of Progesterone can be increased when it is combined with Daclatasvir.Approved
DactinomycinThe serum concentration of Dactinomycin can be decreased when it is combined with Progesterone.Approved
DalteparinThe therapeutic efficacy of Dalteparin can be decreased when used in combination with Progesterone.Approved
DanaparoidThe therapeutic efficacy of Danaparoid can be decreased when used in combination with Progesterone.Approved, Withdrawn
DapagliflozinThe serum concentration of Dapagliflozin can be decreased when it is combined with Progesterone.Approved
DarifenacinThe metabolism of Progesterone can be decreased when combined with Darifenacin.Approved, Investigational
DarunavirThe serum concentration of Progesterone can be increased when it is combined with Darunavir.Approved
DasatinibThe serum concentration of Progesterone can be increased when it is combined with Dasatinib.Approved, Investigational
DaunorubicinThe serum concentration of Daunorubicin can be decreased when it is combined with Progesterone.Approved
DebrisoquinThe serum concentration of Debrisoquin can be decreased when it is combined with Progesterone.Approved
Decanoic AcidThe therapeutic efficacy of Progesterone can be decreased when used in combination with Decanoic Acid.Experimental
DeferasiroxThe serum concentration of Progesterone can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Progesterone can be decreased when combined with Delavirdine.Approved
DeoxyspergualinThe therapeutic efficacy of Deoxyspergualin can be decreased when used in combination with Progesterone.Investigational
DesipramineThe serum concentration of Progesterone can be increased when it is combined with Desipramine.Approved
DesirudinThe therapeutic efficacy of Desirudin can be decreased when used in combination with Progesterone.Approved
DesloratadineThe serum concentration of Progesterone can be increased when it is combined with Desloratadine.Approved, Investigational
DexamethasoneThe serum concentration of Progesterone can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DextranThe therapeutic efficacy of Dextran can be decreased when used in combination with Progesterone.Approved, Vet Approved
Dextran 40The therapeutic efficacy of Dextran 40 can be decreased when used in combination with Progesterone.Approved
Dextran 70The therapeutic efficacy of Dextran 70 can be decreased when used in combination with Progesterone.Approved
Dextran 75The therapeutic efficacy of Dextran 75 can be decreased when used in combination with Progesterone.Approved
DextromethorphanThe serum concentration of Progesterone can be increased when it is combined with Dextromethorphan.Approved
DiazepamThe serum concentration of Diazepam can be decreased when it is combined with Progesterone.Approved, Illicit, Vet Approved
DiclofenacThe serum concentration of Progesterone can be increased when it is combined with Diclofenac.Approved, Vet Approved
DicoumarolThe therapeutic efficacy of Dicoumarol can be decreased when used in combination with Progesterone.Approved
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Progesterone.Approved
DigitoxinThe serum concentration of Digitoxin can be decreased when it is combined with Progesterone.Approved
DigoxinThe serum concentration of Progesterone can be decreased when it is combined with Digoxin.Approved
DihydroergotamineThe metabolism of Progesterone can be decreased when combined with Dihydroergotamine.Approved
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be decreased when it is combined with Progesterone.Illicit
DiltiazemThe metabolism of Progesterone can be decreased when combined with Diltiazem.Approved
DiphenhydramineThe metabolism of Progesterone can be decreased when combined with Diphenhydramine.Approved
DipyridamoleThe serum concentration of Dipyridamole can be decreased when it is combined with Progesterone.Approved
DocetaxelThe serum concentration of Docetaxel can be decreased when it is combined with Progesterone.Approved, Investigational
DomperidoneThe serum concentration of Domperidone can be decreased when it is combined with Progesterone.Approved, Investigational, Vet Approved
DoxazosinThe serum concentration of Progesterone can be increased when it is combined with Doxazosin.Approved
DoxepinThe serum concentration of Progesterone can be increased when it is combined with Doxepin.Approved
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Progesterone.Approved, Investigational
DoxorubicinThe serum concentration of Doxorubicin can be decreased when it is combined with Progesterone.Approved, Investigational
DoxycyclineThe metabolism of Progesterone can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronabinolThe serum concentration of Progesterone can be increased when it is combined with Dronabinol.Approved, Illicit
DronedaroneThe metabolism of Progesterone can be decreased when combined with Dronedarone.Approved
DulaglutideThe therapeutic efficacy of Dulaglutide can be decreased when used in combination with Progesterone.Approved
DuloxetineThe metabolism of Progesterone can be decreased when combined with Duloxetine.Approved
EconazoleThe therapeutic efficacy of Progesterone can be decreased when used in combination with Econazole.Approved
Edetic AcidThe therapeutic efficacy of Edetic Acid can be decreased when used in combination with Progesterone.Approved, Vet Approved
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Progesterone.Approved
EfavirenzThe serum concentration of Progesterone can be decreased when it is combined with Efavirenz.Approved, Investigational
EfinaconazoleThe therapeutic efficacy of Progesterone can be decreased when used in combination with Efinaconazole.Approved
ElbasvirThe serum concentration of Progesterone can be increased when it is combined with Elbasvir.Approved
EletriptanThe serum concentration of Eletriptan can be decreased when it is combined with Progesterone.Approved, Investigational
EliglustatThe metabolism of Progesterone can be decreased when combined with Eliglustat.Approved
EmpagliflozinThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Progesterone.Approved
EnalaprilThe serum concentration of Progesterone can be increased when it is combined with Enalapril.Approved, Vet Approved
EnoxaparinThe therapeutic efficacy of Enoxaparin can be decreased when used in combination with Progesterone.Approved
EnzalutamideThe serum concentration of Progesterone can be decreased when it is combined with Enzalutamide.Approved
EpinastineThe serum concentration of Epinastine can be decreased when it is combined with Progesterone.Approved, Investigational
ErgonovineThe serum concentration of Progesterone can be increased when it is combined with Ergonovine.Approved
ErgotamineThe serum concentration of Progesterone can be increased when it is combined with Ergotamine.Approved
ErlotinibThe serum concentration of Erlotinib can be decreased when it is combined with Progesterone.Approved, Investigational
ErythromycinThe metabolism of Progesterone can be decreased when combined with Erythromycin.Approved, Vet Approved
Eslicarbazepine acetateThe serum concentration of Progesterone can be decreased when it is combined with Eslicarbazepine acetate.Approved
EsomeprazoleThe metabolism of Progesterone can be decreased when combined with Esomeprazole.Approved, Investigational
EstradiolThe serum concentration of Estradiol can be decreased when it is combined with Progesterone.Approved, Investigational, Vet Approved
EstramustineThe serum concentration of Progesterone can be increased when it is combined with Estramustine.Approved
EstriolThe serum concentration of Estriol can be decreased when it is combined with Progesterone.Approved, Vet Approved
EstroneThe serum concentration of Estrone can be decreased when it is combined with Progesterone.Approved
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Progesterone.Approved
Ethyl biscoumacetateThe therapeutic efficacy of Ethyl biscoumacetate can be decreased when used in combination with Progesterone.Withdrawn
EtoposideThe serum concentration of Etoposide can be decreased when it is combined with Progesterone.Approved
EtravirineThe serum concentration of Progesterone can be decreased when it is combined with Etravirine.Approved
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Progesterone.Approved
ExenatideThe therapeutic efficacy of Exenatide can be decreased when used in combination with Progesterone.Approved, Investigational
EzetimibeThe serum concentration of Ezetimibe can be decreased when it is combined with Progesterone.Approved
FelodipineThe serum concentration of Progesterone can be increased when it is combined with Felodipine.Approved, Investigational
FentanylThe serum concentration of Progesterone can be increased when it is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FesoterodineThe serum concentration of Fesoterodine can be decreased when it is combined with Progesterone.Approved
FexofenadineThe serum concentration of Fexofenadine can be decreased when it is combined with Progesterone.Approved
FidaxomicinThe serum concentration of Fidaxomicin can be decreased when it is combined with Progesterone.Approved
FloxuridineThe metabolism of Progesterone can be decreased when combined with Floxuridine.Approved
FluconazoleThe therapeutic efficacy of Progesterone can be decreased when used in combination with Fluconazole.Approved
FlucytosineThe therapeutic efficacy of Progesterone can be decreased when used in combination with Flucytosine.Approved
FluindioneThe therapeutic efficacy of Fluindione can be decreased when used in combination with Progesterone.Investigational
FluorouracilThe metabolism of Progesterone can be decreased when combined with Fluorouracil.Approved
FluoxetineThe metabolism of Progesterone can be decreased when combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe serum concentration of Progesterone can be increased when it is combined with Flupentixol.Approved, Withdrawn
FluphenazineThe serum concentration of Progesterone can be increased when it is combined with Fluphenazine.Approved
FlurazepamThe serum concentration of Progesterone can be increased when it is combined with Flurazepam.Approved, Illicit
Fluticasone furoateThe serum concentration of Fluticasone furoate can be decreased when it is combined with Progesterone.Approved
FluvastatinThe metabolism of Progesterone can be decreased when combined with Fluvastatin.Approved
FluvoxamineThe metabolism of Progesterone can be decreased when combined with Fluvoxamine.Approved, Investigational
FondaparinuxThe therapeutic efficacy of Fondaparinux can be decreased when used in combination with Progesterone.Investigational
Fondaparinux sodiumThe therapeutic efficacy of Fondaparinux sodium can be decreased when used in combination with Progesterone.Approved, Investigational
FosamprenavirThe metabolism of Progesterone can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Progesterone can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe metabolism of Progesterone can be increased when combined with Fosphenytoin.Approved
Fusidic AcidThe serum concentration of Progesterone can be increased when it is combined with Fusidic Acid.Approved
GabexateThe therapeutic efficacy of Gabexate can be decreased when used in combination with Progesterone.Investigational
GefitinibThe serum concentration of Gefitinib can be decreased when it is combined with Progesterone.Approved, Investigational
GemcitabineThe serum concentration of Gemcitabine can be decreased when it is combined with Progesterone.Approved
GemfibrozilThe metabolism of Progesterone can be decreased when combined with Gemfibrozil.Approved
GenisteinThe serum concentration of Progesterone can be increased when it is combined with Genistein.Investigational
GlibornurideThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Progesterone.Withdrawn
GliclazideThe therapeutic efficacy of Gliclazide can be decreased when used in combination with Progesterone.Approved
GlimepirideThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Progesterone.Approved
GlipizideThe therapeutic efficacy of Glipizide can be decreased when used in combination with Progesterone.Approved
GliquidoneThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Progesterone.Approved
GlyburideThe serum concentration of Progesterone can be increased when it is combined with Glyburide.Approved
GlycerolThe serum concentration of Progesterone can be increased when it is combined with Glycerol.Experimental
GlyphosateThe therapeutic efficacy of Progesterone can be decreased when used in combination with Glyphosate.Experimental
Gramicidin DThe serum concentration of Progesterone can be increased when it is combined with Gramicidin D.Approved
GrazoprevirThe serum concentration of Grazoprevir can be decreased when it is combined with Progesterone.Approved
GrepafloxacinThe serum concentration of Grepafloxacin can be decreased when it is combined with Progesterone.Withdrawn
GriseofulvinThe therapeutic efficacy of Progesterone can be decreased when used in combination with Griseofulvin.Approved, Vet Approved
GusperimusThe therapeutic efficacy of Gusperimus can be decreased when used in combination with Progesterone.Investigational
HaloperidolThe serum concentration of Haloperidol can be decreased when it is combined with Progesterone.Approved
HaloproginThe therapeutic efficacy of Progesterone can be decreased when used in combination with Haloprogin.Approved, Withdrawn
HeparinThe therapeutic efficacy of Heparin can be decreased when used in combination with Progesterone.Approved, Investigational
HexetidineThe therapeutic efficacy of Progesterone can be decreased when used in combination with Hexetidine.Approved
HirulogThe therapeutic efficacy of Hirulog can be decreased when used in combination with Progesterone.Experimental
HydrocortisoneThe serum concentration of Hydrocortisone can be decreased when it is combined with Progesterone.Approved, Vet Approved
IbuprofenThe serum concentration of Ibuprofen can be decreased when it is combined with Progesterone.Approved
IdelalisibThe serum concentration of Progesterone can be increased when it is combined with Idelalisib.Approved
idraparinuxThe therapeutic efficacy of idraparinux can be decreased when used in combination with Progesterone.Investigational
ImatinibThe metabolism of Progesterone can be decreased when combined with Imatinib.Approved
ImipramineThe serum concentration of Imipramine can be decreased when it is combined with Progesterone.Approved
IndacaterolThe serum concentration of Indacaterol can be decreased when it is combined with Progesterone.Approved
IndinavirThe metabolism of Progesterone can be decreased when combined with Indinavir.Approved
IndomethacinThe serum concentration of Indomethacin can be decreased when it is combined with Progesterone.Approved, Investigational
Insulin AspartThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Progesterone.Approved
Insulin DetemirThe therapeutic efficacy of Insulin Detemir can be decreased when used in combination with Progesterone.Approved
Insulin GlargineThe therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Progesterone.Approved
Insulin GlulisineThe therapeutic efficacy of Insulin Glulisine can be decreased when used in combination with Progesterone.Approved
Insulin LisproThe therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Progesterone.Approved
Insulin PorkThe therapeutic efficacy of Insulin Pork can be decreased when used in combination with Progesterone.Approved
IrbesartanThe metabolism of Progesterone can be decreased when combined with Irbesartan.Approved, Investigational
IrinotecanThe serum concentration of Irinotecan can be decreased when it is combined with Progesterone.Approved, Investigational
IsavuconazoniumThe metabolism of Progesterone can be decreased when combined with Isavuconazonium.Approved, Investigational
IsoconazoleThe therapeutic efficacy of Progesterone can be decreased when used in combination with Isoconazole.Approved
IsoniazidThe metabolism of Progesterone can be decreased when combined with Isoniazid.Approved
IsradipineThe metabolism of Progesterone can be decreased when combined with Isradipine.Approved
ItraconazoleThe therapeutic efficacy of Progesterone can be decreased when used in combination with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Progesterone can be increased when it is combined with Ivacaftor.Approved
IvermectinThe serum concentration of Ivermectin can be decreased when it is combined with Progesterone.Approved, Vet Approved
KetamineThe serum concentration of Progesterone can be increased when it is combined with Ketamine.Approved, Vet Approved
KetazolamThe serum concentration of Ketazolam can be decreased when it is combined with Progesterone.Approved
KetoconazoleThe therapeutic efficacy of Progesterone can be decreased when used in combination with Ketoconazole.Approved, Investigational
LamivudineThe serum concentration of Lamivudine can be decreased when it is combined with Progesterone.Approved, Investigational
LamotrigineThe serum concentration of Lamotrigine can be decreased when it is combined with Progesterone.Approved, Investigational
LansoprazoleThe serum concentration of Lansoprazole can be decreased when it is combined with Progesterone.Approved, Investigational
LapatinibThe serum concentration of Progesterone can be increased when it is combined with Lapatinib.Approved, Investigational
LedipasvirThe serum concentration of Ledipasvir can be decreased when it is combined with Progesterone.Approved
LeflunomideThe metabolism of Progesterone can be decreased when combined with Leflunomide.Approved, Investigational
LenalidomideThe serum concentration of Lenalidomide can be decreased when it is combined with Progesterone.Approved
LenvatinibThe serum concentration of Lenvatinib can be decreased when it is combined with Progesterone.Approved
LepirudinThe therapeutic efficacy of Lepirudin can be decreased when used in combination with Progesterone.Approved
LevetiracetamThe serum concentration of Levetiracetam can be decreased when it is combined with Progesterone.Approved, Investigational
LevofloxacinThe serum concentration of Levofloxacin can be decreased when it is combined with Progesterone.Approved, Investigational
LevomilnacipranThe serum concentration of Levomilnacipran can be decreased when it is combined with Progesterone.Approved
LevothyroxineThe serum concentration of Progesterone can be decreased when it is combined with Levothyroxine.Approved
LidocaineThe serum concentration of Progesterone can be increased when it is combined with Lidocaine.Approved, Vet Approved
LinagliptinThe serum concentration of Linagliptin can be decreased when it is combined with Progesterone.Approved
LiothyronineThe serum concentration of Progesterone can be decreased when it is combined with Liothyronine.Approved, Vet Approved
LiotrixThe serum concentration of Progesterone can be decreased when it is combined with Liotrix.Approved
LiraglutideThe therapeutic efficacy of Liraglutide can be decreased when used in combination with Progesterone.Approved
LisinoprilThe serum concentration of Progesterone can be increased when it is combined with Lisinopril.Approved, Investigational
LomitapideThe serum concentration of Progesterone can be increased when it is combined with Lomitapide.Approved
LoperamideThe serum concentration of Loperamide can be decreased when it is combined with Progesterone.Approved
LopinavirThe metabolism of Progesterone can be decreased when combined with Lopinavir.Approved
LoratadineThe serum concentration of Progesterone can be increased when it is combined with Loratadine.Approved
LorcaserinThe metabolism of Progesterone can be decreased when combined with Lorcaserin.Approved
LosartanThe serum concentration of Losartan can be decreased when it is combined with Progesterone.Approved
LovastatinThe metabolism of Progesterone can be decreased when combined with Lovastatin.Approved, Investigational
LuliconazoleThe serum concentration of Progesterone can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Progesterone can be increased when it is combined with Lumacaftor.Approved
LumefantrineThe metabolism of Progesterone can be decreased when combined with Lumefantrine.Approved
MannitolThe serum concentration of Mannitol can be decreased when it is combined with Progesterone.Approved, Investigational
MaprotilineThe serum concentration of Progesterone can be increased when it is combined with Maprotiline.Approved
MebendazoleThe serum concentration of Progesterone can be increased when it is combined with Mebendazole.Approved, Vet Approved
MefloquineThe serum concentration of Progesterone can be increased when it is combined with Mefloquine.Approved
Megestrol acetateThe serum concentration of Progesterone can be increased when it is combined with Megestrol acetate.Approved, Vet Approved
MeprobamateThe serum concentration of Progesterone can be increased when it is combined with Meprobamate.Approved, Illicit
MetforminThe therapeutic efficacy of Metformin can be decreased when used in combination with Progesterone.Approved
MethadoneThe serum concentration of Progesterone can be increased when it is combined with Methadone.Approved
MethotrexateThe serum concentration of Methotrexate can be decreased when it is combined with Progesterone.Approved
MethotrimeprazineThe metabolism of Progesterone can be decreased when combined with Methotrimeprazine.Approved
MethylprednisoloneThe serum concentration of Methylprednisolone can be decreased when it is combined with Progesterone.Approved, Vet Approved
MetoprololThe serum concentration of Metoprolol can be decreased when it is combined with Progesterone.Approved, Investigational
MevastatinThe therapeutic efficacy of Progesterone can be decreased when used in combination with Mevastatin.Experimental
MexiletineThe metabolism of Progesterone can be decreased when combined with Mexiletine.Approved
MibefradilThe serum concentration of Progesterone can be increased when it is combined with Mibefradil.Withdrawn
MicafunginThe therapeutic efficacy of Progesterone can be decreased when used in combination with Micafungin.Approved, Investigational
MiconazoleThe therapeutic efficacy of Progesterone can be decreased when used in combination with Miconazole.Approved, Investigational, Vet Approved
MidazolamThe serum concentration of Midazolam can be decreased when it is combined with Progesterone.Approved, Illicit
MifepristoneThe serum concentration of Progesterone can be increased when it is combined with Mifepristone.Approved, Investigational
MiglitolThe therapeutic efficacy of Miglitol can be decreased when used in combination with Progesterone.Approved
MiglustatThe therapeutic efficacy of Miglustat can be decreased when used in combination with Progesterone.Approved
MiltefosineThe therapeutic efficacy of Progesterone can be decreased when used in combination with Miltefosine.Approved
MirabegronThe serum concentration of Mirabegron can be decreased when it is combined with Progesterone.Approved
MitiglinideThe therapeutic efficacy of Mitiglinide can be decreased when used in combination with Progesterone.Approved, Investigational
MitomycinThe serum concentration of Progesterone can be increased when it is combined with Mitomycin.Approved
MitotaneThe serum concentration of Progesterone can be decreased when it is combined with Mitotane.Approved
MitoxantroneThe serum concentration of Mitoxantrone can be decreased when it is combined with Progesterone.Approved, Investigational
MoclobemideThe metabolism of Progesterone can be decreased when combined with Moclobemide.Approved
ModafinilThe serum concentration of Progesterone can be decreased when it is combined with Modafinil.Approved, Investigational
MonensinThe therapeutic efficacy of Progesterone can be decreased when used in combination with Monensin.Vet Approved
MorphineThe serum concentration of Morphine can be decreased when it is combined with Progesterone.Approved, Investigational
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be decreased when it is combined with Progesterone.Approved, Investigational
MyxothiazolThe therapeutic efficacy of Progesterone can be decreased when used in combination with Myxothiazol.Experimental
NadololThe serum concentration of Nadolol can be decreased when it is combined with Progesterone.Approved
NadroparinThe therapeutic efficacy of Nadroparin can be decreased when used in combination with Progesterone.Approved
NafamostatThe therapeutic efficacy of Nafamostat can be decreased when used in combination with Progesterone.Investigational
NafcillinThe serum concentration of Progesterone can be decreased when it is combined with Nafcillin.Approved
NaftifineThe therapeutic efficacy of Progesterone can be decreased when used in combination with Naftifine.Approved
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Progesterone.Approved
NaloxoneThe serum concentration of Naloxone can be decreased when it is combined with Progesterone.Approved, Vet Approved
NaltrexoneThe serum concentration of Progesterone can be increased when it is combined with Naltrexone.Approved, Investigational, Vet Approved
NaringeninThe serum concentration of Progesterone can be increased when it is combined with Naringenin.Experimental
NatamycinThe therapeutic efficacy of Progesterone can be decreased when used in combination with Natamycin.Approved
NateglinideThe therapeutic efficacy of Nateglinide can be decreased when used in combination with Progesterone.Approved, Investigational
NefazodoneThe metabolism of Progesterone can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Progesterone can be decreased when combined with Nelfinavir.Approved
NeostigmineThe serum concentration of Progesterone can be increased when it is combined with Neostigmine.Approved, Vet Approved
NetupitantThe serum concentration of Progesterone can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Progesterone can be increased when combined with Nevirapine.Approved
NicardipineThe metabolism of Progesterone can be decreased when combined with Nicardipine.Approved
NicotineThe metabolism of Progesterone can be decreased when combined with Nicotine.Approved
NifedipineThe serum concentration of Progesterone can be decreased when it is combined with Nifedipine.Approved
NilotinibThe metabolism of Progesterone can be decreased when combined with Nilotinib.Approved, Investigational
NintedanibThe serum concentration of Nintedanib can be decreased when it is combined with Progesterone.Approved
NisoldipineThe serum concentration of Progesterone can be increased when it is combined with Nisoldipine.Approved
NitrazepamThe serum concentration of Progesterone can be increased when it is combined with Nitrazepam.Approved
NitrendipineThe serum concentration of Progesterone can be increased when it is combined with Nitrendipine.Approved
NitroxolineThe therapeutic efficacy of Progesterone can be decreased when used in combination with Nitroxoline.Approved
NizatidineThe serum concentration of Nizatidine can be decreased when it is combined with Progesterone.Approved
NorethisteroneThe serum concentration of Progesterone can be decreased when it is combined with Norethisterone.Approved
NystatinThe therapeutic efficacy of Progesterone can be decreased when used in combination with Nystatin.Approved, Vet Approved
OlanzapineThe serum concentration of Olanzapine can be decreased when it is combined with Progesterone.Approved, Investigational
OlaparibThe metabolism of Progesterone can be decreased when combined with Olaparib.Approved
OmbitasvirThe serum concentration of Ombitasvir can be decreased when it is combined with Progesterone.Approved
OmeprazoleThe serum concentration of Progesterone can be increased when it is combined with Omeprazole.Approved, Investigational, Vet Approved
OsimertinibThe serum concentration of Progesterone can be increased when it is combined with Osimertinib.Approved
OtamixabanThe therapeutic efficacy of Otamixaban can be decreased when used in combination with Progesterone.Investigational
OxiconazoleThe therapeutic efficacy of Progesterone can be decreased when used in combination with Oxiconazole.Approved
P-NitrophenolThe serum concentration of Progesterone can be increased when it is combined with P-Nitrophenol.Experimental
PaclitaxelThe serum concentration of Paclitaxel can be decreased when it is combined with Progesterone.Approved, Vet Approved
pafuramidineThe therapeutic efficacy of Progesterone can be decreased when used in combination with pafuramidine.Investigational
PalbociclibThe serum concentration of Progesterone can be increased when it is combined with Palbociclib.Approved
Palmitic AcidThe serum concentration of Progesterone can be increased when it is combined with Palmitic Acid.Experimental
PanobinostatThe serum concentration of Progesterone can be increased when it is combined with Panobinostat.Approved, Investigational
PantoprazoleThe serum concentration of Progesterone can be increased when it is combined with Pantoprazole.Approved
ParoxetineThe metabolism of Progesterone can be decreased when combined with Paroxetine.Approved, Investigational
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Progesterone.Approved
Peginterferon alfa-2bThe serum concentration of Progesterone can be decreased when it is combined with Peginterferon alfa-2b.Approved
PentamidineThe therapeutic efficacy of Progesterone can be decreased when used in combination with Pentamidine.Approved
PentobarbitalThe metabolism of Progesterone can be increased when combined with Pentobarbital.Approved, Vet Approved
Pentosan PolysulfateThe therapeutic efficacy of Pentosan Polysulfate can be decreased when used in combination with Progesterone.Approved
PerindoprilThe serum concentration of Progesterone can be increased when it is combined with Perindopril.Approved
PhenforminThe therapeutic efficacy of Phenformin can be decreased when used in combination with Progesterone.Approved, Withdrawn
PhenindioneThe therapeutic efficacy of Phenindione can be decreased when used in combination with Progesterone.Approved
PhenobarbitalThe metabolism of Progesterone can be increased when combined with Phenobarbital.Approved
PhenprocoumonThe therapeutic efficacy of Phenprocoumon can be decreased when used in combination with Progesterone.Approved
PhenytoinThe metabolism of Progesterone can be increased when combined with Phenytoin.Approved, Vet Approved
PimozideThe serum concentration of Progesterone can be increased when it is combined with Pimozide.Approved
PioglitazoneThe therapeutic efficacy of Pioglitazone can be decreased when used in combination with Progesterone.Approved, Investigational
PitavastatinThe serum concentration of Pitavastatin can be decreased when it is combined with Progesterone.Approved
Platelet Activating FactorThe serum concentration of Progesterone can be decreased when it is combined with Platelet Activating Factor.Experimental
PomalidomideThe serum concentration of Pomalidomide can be decreased when it is combined with Progesterone.Approved
PonatinibThe serum concentration of Ponatinib can be decreased when it is combined with Progesterone.Approved
PosaconazoleThe therapeutic efficacy of Progesterone can be decreased when used in combination with Posaconazole.Approved, Investigational, Vet Approved
PramlintideThe therapeutic efficacy of Pramlintide can be decreased when used in combination with Progesterone.Approved, Investigational
PravastatinThe serum concentration of Pravastatin can be decreased when it is combined with Progesterone.Approved
PrazosinThe serum concentration of Prazosin can be decreased when it is combined with Progesterone.Approved
PrednisoloneThe serum concentration of Prednisolone can be decreased when it is combined with Progesterone.Approved, Vet Approved
PrednisoneThe serum concentration of Prednisone can be decreased when it is combined with Progesterone.Approved, Vet Approved
PrimidoneThe metabolism of Progesterone can be increased when combined with Primidone.Approved, Vet Approved
ProbenecidThe serum concentration of Progesterone can be increased when it is combined with Probenecid.Approved
PromazineThe metabolism of Progesterone can be decreased when combined with Promazine.Approved, Vet Approved
PromethazineThe serum concentration of Progesterone can be increased when it is combined with Promethazine.Approved
PropafenoneThe serum concentration of Progesterone can be increased when it is combined with Propafenone.Approved
PropranololThe serum concentration of Propranolol can be decreased when it is combined with Progesterone.Approved, Investigational
Protein CThe therapeutic efficacy of Protein C can be decreased when used in combination with Progesterone.Approved
Protein S humanThe therapeutic efficacy of Protein S human can be decreased when used in combination with Progesterone.Approved
ProtocatechualdehydeThe therapeutic efficacy of Protocatechualdehyde can be decreased when used in combination with Progesterone.Approved
ProtriptylineThe serum concentration of Progesterone can be increased when it is combined with Protriptyline.Approved
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Progesterone.Approved
PyrimethamineThe metabolism of Progesterone can be decreased when combined with Pyrimethamine.Approved, Vet Approved
QuercetinThe serum concentration of Progesterone can be increased when it is combined with Quercetin.Experimental
QuetiapineThe serum concentration of Quetiapine can be decreased when it is combined with Progesterone.Approved
QuinacrineThe serum concentration of Progesterone can be increased when it is combined with Quinacrine.Approved
QuinidineThe metabolism of Progesterone can be decreased when combined with Quinidine.Approved
QuinineThe serum concentration of Quinine can be decreased when it is combined with Progesterone.Approved
RabeprazoleThe metabolism of Progesterone can be decreased when combined with Rabeprazole.Approved, Investigational
RadicicolThe therapeutic efficacy of Progesterone can be decreased when used in combination with Radicicol.Experimental
RanitidineThe serum concentration of Ranitidine can be decreased when it is combined with Progesterone.Approved
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Progesterone.Approved, Investigational
ReboxetineThe serum concentration of Progesterone can be increased when it is combined with Reboxetine.Approved, Investigational
RegorafenibThe serum concentration of Progesterone can be increased when it is combined with Regorafenib.Approved
RepaglinideThe therapeutic efficacy of Repaglinide can be decreased when used in combination with Progesterone.Approved, Investigational
ReserpineThe serum concentration of Progesterone can be decreased when it is combined with Reserpine.Approved
ReviparinThe therapeutic efficacy of Reviparin can be decreased when used in combination with Progesterone.Approved
RifabutinThe metabolism of Progesterone can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Progesterone can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Progesterone can be increased when combined with Rifapentine.Approved
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Progesterone.Approved, Investigational
RilpivirineThe serum concentration of Progesterone can be increased when it is combined with Rilpivirine.Approved
RisperidoneThe serum concentration of Risperidone can be decreased when it is combined with Progesterone.Approved, Investigational
RitonavirThe metabolism of Progesterone can be decreased when combined with Ritonavir.Approved, Investigational
RivaroxabanThe therapeutic efficacy of Rivaroxaban can be decreased when used in combination with Progesterone.Approved
RolapitantThe serum concentration of Progesterone can be increased when it is combined with Rolapitant.Approved
RomidepsinThe serum concentration of Romidepsin can be decreased when it is combined with Progesterone.Approved, Investigational
RopiniroleThe metabolism of Progesterone can be decreased when combined with Ropinirole.Approved, Investigational
RosiglitazoneThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Progesterone.Approved, Investigational
Salicylhydroxamic AcidThe therapeutic efficacy of Progesterone can be decreased when used in combination with Salicylhydroxamic Acid.Experimental
Salicylic acidThe therapeutic efficacy of Progesterone can be decreased when used in combination with Salicylic acid.Approved, Vet Approved
SaquinavirThe metabolism of Progesterone can be decreased when combined with Saquinavir.Approved, Investigational
SaxagliptinThe serum concentration of Saxagliptin can be decreased when it is combined with Progesterone.Approved
ScopolamineThe serum concentration of Progesterone can be increased when it is combined with Scopolamine.Approved
SecobarbitalThe metabolism of Progesterone can be increased when combined with Secobarbital.Approved, Vet Approved
SelegilineThe serum concentration of Progesterone can be increased when it is combined with Selegiline.Approved, Investigational, Vet Approved
SelexipagThe serum concentration of Selexipag can be decreased when it is combined with Progesterone.Approved
SertaconazoleThe therapeutic efficacy of Progesterone can be decreased when used in combination with Sertaconazole.Approved
SertralineThe serum concentration of Progesterone can be increased when it is combined with Sertraline.Approved
SildenafilThe metabolism of Progesterone can be decreased when combined with Sildenafil.Approved, Investigational
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Progesterone.Approved
SiltuximabThe serum concentration of Progesterone can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Progesterone can be increased when it is combined with Simeprevir.Approved
SimvastatinThe serum concentration of Progesterone can be increased when it is combined with Simvastatin.Approved
SinefunginThe therapeutic efficacy of Progesterone can be decreased when used in combination with Sinefungin.Experimental
SirolimusThe therapeutic efficacy of Progesterone can be decreased when used in combination with Sirolimus.Approved, Investigational
SitagliptinThe serum concentration of Sitagliptin can be decreased when it is combined with Progesterone.Approved, Investigational
SofosbuvirThe serum concentration of Sofosbuvir can be decreased when it is combined with Progesterone.Approved
SorafenibThe serum concentration of Sorafenib can be decreased when it is combined with Progesterone.Approved, Investigational
SparfloxacinThe serum concentration of Sparfloxacin can be decreased when it is combined with Progesterone.Approved
SphingosineThe serum concentration of Sphingosine can be decreased when it is combined with Progesterone.Experimental
SpironolactoneThe serum concentration of Progesterone can be increased when it is combined with Spironolactone.Approved
St. John's WortThe serum concentration of Progesterone can be decreased when it is combined with St. John's Wort.Nutraceutical
StaurosporineThe serum concentration of Progesterone can be increased when it is combined with Staurosporine.Experimental
StiripentolThe serum concentration of Progesterone can be increased when it is combined with Stiripentol.Approved
StreptozocinThe serum concentration of Progesterone can be decreased when it is combined with Streptozocin.Approved
SulconazoleThe therapeutic efficacy of Progesterone can be decreased when used in combination with Sulconazole.Approved
SulfadiazineThe metabolism of Progesterone can be decreased when combined with Sulfadiazine.Approved, Vet Approved
SulfamethoxazoleThe metabolism of Progesterone can be decreased when combined with Sulfamethoxazole.Approved
SulfinpyrazoneThe serum concentration of Progesterone can be increased when it is combined with Sulfinpyrazone.Approved
SulfisoxazoleThe metabolism of Progesterone can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulodexideThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Progesterone.Approved, Investigational
SumatriptanThe serum concentration of Progesterone can be increased when it is combined with Sumatriptan.Approved, Investigational
SunitinibThe serum concentration of Progesterone can be increased when it is combined with Sunitinib.Approved, Investigational
TacrineThe serum concentration of Progesterone can be increased when it is combined with Tacrine.Withdrawn
TacrolimusThe serum concentration of Tacrolimus can be decreased when it is combined with Progesterone.Approved, Investigational
TamoxifenThe serum concentration of Tamoxifen can be decreased when it is combined with Progesterone.Approved
Taurocholic AcidThe serum concentration of Taurocholic Acid can be decreased when it is combined with Progesterone.Experimental
TavaboroleThe therapeutic efficacy of Progesterone can be decreased when used in combination with Tavaborole.Approved
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be decreased when it is combined with Progesterone.Approved
TelaprevirThe metabolism of Progesterone can be decreased when combined with Telaprevir.Approved
TelithromycinThe metabolism of Progesterone can be decreased when combined with Telithromycin.Approved
TelmisartanThe serum concentration of Progesterone can be increased when it is combined with Telmisartan.Approved, Investigational
TemsirolimusThe serum concentration of Temsirolimus can be decreased when it is combined with Progesterone.Approved
TenofovirThe metabolism of Progesterone can be decreased when combined with Tenofovir.Approved, Investigational
TerazosinThe serum concentration of Progesterone can be increased when it is combined with Terazosin.Approved
TerbinafineThe therapeutic efficacy of Progesterone can be decreased when used in combination with Terbinafine.Approved, Investigational, Vet Approved
TerconazoleThe therapeutic efficacy of Progesterone can be decreased when used in combination with Terconazole.Approved
TerfenadineThe serum concentration of Progesterone can be increased when it is combined with Terfenadine.Withdrawn
TeriflunomideThe serum concentration of Progesterone can be decreased when it is combined with Teriflunomide.Approved
TesmilifeneThe serum concentration of Progesterone can be decreased when it is combined with Tesmilifene.Investigational
TestosteroneThe serum concentration of Progesterone can be increased when it is combined with Testosterone.Approved, Investigational
TheophyllineThe metabolism of Progesterone can be decreased when combined with Theophylline.Approved
ThiazolidinedioneThe therapeutic efficacy of Thiazolidinedione can be decreased when used in combination with Progesterone.Investigational
ThioridazineThe metabolism of Progesterone can be decreased when combined with Thioridazine.Approved
ThymolThe therapeutic efficacy of Progesterone can be decreased when used in combination with Thymol.Approved
TicagrelorThe serum concentration of Ticagrelor can be decreased when it is combined with Progesterone.Approved
TiclopidineThe metabolism of Progesterone can be decreased when combined with Ticlopidine.Approved
TimololThe serum concentration of Timolol can be decreased when it is combined with Progesterone.Approved
TioconazoleThe therapeutic efficacy of Progesterone can be decreased when used in combination with Tioconazole.Approved
TipranavirThe metabolism of Progesterone can be decreased when combined with Tipranavir.Approved, Investigational
TocilizumabThe serum concentration of Progesterone can be decreased when it is combined with Tocilizumab.Approved
TolazamideThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Progesterone.Approved
TolbutamideThe metabolism of Progesterone can be decreased when combined with Tolbutamide.Approved
TolnaftateThe therapeutic efficacy of Progesterone can be decreased when used in combination with Tolnaftate.Approved, Vet Approved
TolvaptanThe serum concentration of Tolvaptan can be decreased when it is combined with Progesterone.Approved
TopiramateThe metabolism of Progesterone can be decreased when combined with Topiramate.Approved
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Progesterone.Approved, Investigational
ToremifeneThe serum concentration of Toremifene can be decreased when it is combined with Progesterone.Approved, Investigational
TranylcypromineThe metabolism of Progesterone can be decreased when combined with Tranylcypromine.Approved
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be decreased when it is combined with Progesterone.Approved
TrazodoneThe serum concentration of Progesterone can be decreased when it is combined with Trazodone.Approved, Investigational
TrifluoperazineThe serum concentration of Progesterone can be increased when it is combined with Trifluoperazine.Approved
TriflupromazineThe serum concentration of Progesterone can be increased when it is combined with Triflupromazine.Approved, Vet Approved
TrimethoprimThe serum concentration of Progesterone can be decreased when it is combined with Trimethoprim.Approved, Vet Approved
TrimetrexateThe therapeutic efficacy of Progesterone can be decreased when used in combination with Trimetrexate.Approved, Investigational
TrimipramineThe serum concentration of Progesterone can be increased when it is combined with Trimipramine.Approved
TroglitazoneThe therapeutic efficacy of Troglitazone can be decreased when used in combination with Progesterone.Withdrawn
TroleandomycinThe serum concentration of Progesterone can be increased when it is combined with Troleandomycin.Approved
UlipristalThe therapeutic efficacy of Progesterone can be decreased when used in combination with Ulipristal.Approved
UmeclidiniumThe serum concentration of Umeclidinium can be decreased when it is combined with Progesterone.Approved
Valproic AcidThe metabolism of Progesterone can be decreased when combined with Valproic Acid.Approved, Investigational
ValsartanThe metabolism of Progesterone can be decreased when combined with Valsartan.Approved, Investigational
VecuroniumThe serum concentration of Vecuronium can be decreased when it is combined with Progesterone.Approved
VemurafenibThe serum concentration of Progesterone can be increased when it is combined with Vemurafenib.Approved
VenetoclaxThe serum concentration of Venetoclax can be decreased when it is combined with Progesterone.Approved
VenlafaxineThe metabolism of Progesterone can be decreased when combined with Venlafaxine.Approved
VerapamilThe metabolism of Progesterone can be decreased when combined with Verapamil.Approved
VildagliptinThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Progesterone.Approved, Investigational
VinblastineThe serum concentration of Vinblastine can be decreased when it is combined with Progesterone.Approved
VincristineThe serum concentration of Vincristine can be decreased when it is combined with Progesterone.Approved, Investigational
VinorelbineThe serum concentration of Progesterone can be increased when it is combined with Vinorelbine.Approved, Investigational
VismodegibThe serum concentration of Vismodegib can be decreased when it is combined with Progesterone.Approved
VogliboseThe therapeutic efficacy of Voglibose can be decreased when used in combination with Progesterone.Approved, Investigational
VoriconazoleThe therapeutic efficacy of Progesterone can be decreased when used in combination with Voriconazole.Approved, Investigational
WarfarinThe therapeutic efficacy of Warfarin can be decreased when used in combination with Progesterone.Approved
XimelagatranThe therapeutic efficacy of Ximelagatran can be decreased when used in combination with Progesterone.Approved, Investigational, Withdrawn
Ym150The therapeutic efficacy of Ym150 can be decreased when used in combination with Progesterone.Investigational
ZafirlukastThe metabolism of Progesterone can be decreased when combined with Zafirlukast.Approved, Investigational
ZidovudineThe serum concentration of Zidovudine can be decreased when it is combined with Progesterone.Approved
ZimelidineThe serum concentration of Progesterone can be increased when it is combined with Zimelidine.Withdrawn
ZiprasidoneThe metabolism of Progesterone can be decreased when combined with Ziprasidone.Approved
Food Interactions
  • Avoid alcohol.
  • Avoid excessive quantities of coffee or tea (Caffeine).
  • Increase dietary intake of magnesium, folate, vitamin B6, B12, and/or consider taking a multivitamin.
  • Take at the same time everyday.
  • Take with food.
References
Synthesis Reference

Nejib M. Nasraoui, Alain Piasco, “Derivatives of 19-nor progesterone; process for producing them and the pharmaceutical compositions incorporating them.” U.S. Patent US5223492, issued May, 1971.

US5223492
General References
  1. Allen WM: THE ISOLATION OF CRYSTALLINE PROGESTIN. Science. 1935 Aug 2;82(2118):89-93. [PubMed:17747122 ]
  2. Allen WM: Progesterone: how did the name originate? South Med J. 1970 Oct;63(10):1151-5. [PubMed:4922128 ]
  3. Schumacher M, Guennoun R, Robert F, Carelli C, Gago N, Ghoumari A, Gonzalez Deniselle MC, Gonzalez SL, Ibanez C, Labombarda F, Coirini H, Baulieu EE, De Nicola AF: Local synthesis and dual actions of progesterone in the nervous system: neuroprotection and myelination. Growth Horm IGF Res. 2004 Jun;14 Suppl A:S18-33. [PubMed:15135772 ]
  4. Hould FS, Fried GM, Fazekas AG, Tremblay S, Mersereau WA: Progesterone receptors regulate gallbladder motility. J Surg Res. 1988 Dec;45(6):505-12. [PubMed:3184927 ]
External Links
ATC CodesG03DA04G03FA04
AHFS Codes
  • 68:32.00
PDB EntriesNot Available
FDA labelDownload (86.6 KB)
MSDSDownload (74.2 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.982
Caco-2 permeable+0.7724
P-glycoprotein substrateSubstrate0.5449
P-glycoprotein inhibitor IInhibitor0.8841
P-glycoprotein inhibitor IIInhibitor0.6043
Renal organic cation transporterNon-inhibitor0.6931
CYP450 2C9 substrateNon-substrate0.847
CYP450 2D6 substrateNon-substrate0.8795
CYP450 3A4 substrateSubstrate0.7408
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorNon-inhibitor0.9533
CYP450 2C19 inhibitorNon-inhibitor0.6514
CYP450 3A4 inhibitorNon-inhibitor0.8309
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8203
Ames testNon AMES toxic0.9626
CarcinogenicityNon-carcinogens0.9151
BiodegradationNot ready biodegradable0.9575
Rat acute toxicity1.8041 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.7451
hERG inhibition (predictor II)Non-inhibitor0.7454
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Bristol myers squibb
  • Amarin pharmaceuticals inc
  • Solvay pharmaceuticals
  • Esi pharmacal
  • Unimed pharmaceuticals llc
  • Watson laboratories inc
  • App pharmaceuticals llc
  • Eli lilly and co
  • Pharmaforce inc
  • Alza corp
  • Ferring pharmaceuticals inc
Packagers
Dosage forms
FormRouteStrength
SolutionIntramuscular50 mg
GelVaginal45 mg/1.125g
GelVaginal8 %
GelVaginal90 mg/1.125g
InsertVaginal100 mg/1
InsertVaginal100 mg
Capsule; gel, meteredOral; Transdermal
Capsule, liquid filledOral100 mg/1
Capsule, liquid filledOral200 mg/1
InjectionIntramuscular50 mg/1
Injection, solutionIntramuscular50 mg/mL
LiquidIntramuscular50 mg
CapsuleOral100 mg/1
CapsuleOral100 mg
CapsuleOral200 mg/1
Prices
Unit descriptionCostUnit
Prochieve 4% Gel (18 Applicators Per Box)160.18USD tube
Crinone 8% Gel (1 Box = 6 Applications)84.26USD box
Prochieve 8% Gel 1.45 gm Tube14.83USD tube
Crinone 8% gel13.61USD g
Prochieve 8% gel12.0USD g
Prochieve 4% gel8.56USD g
Progesterone 50 mg/ml6.6USD ml
Progesterone oil 50 mg/ml vial3.88USD ml
Prometrium 200 mg capsule3.84USD capsule
First-progesterone vgs 400 susuppositoryp3.33USD each
First-progesterone vgs 200 suppository3.15USD each
First-progesterone vgs 100 suppository3.0USD each
First-progesterone vgs 50 suppository2.93USD each
First-progesterone vgs 25 suppository2.88USD each
Prometrium 100 mg capsule1.69USD capsule
Progesterone powder micronized0.74USD g
Progesterone powder milled0.73USD g
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5543150 No1993-09-152013-09-15Us
US7300664 No1999-11-172019-11-17Us
US7320800 No1999-11-172019-11-17Us
US7393543 No1999-11-172019-11-17Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point121 °CPhysProp
water solubility8.81 mg/L (at 25 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP3.87HANSCH,C ET AL. (1995)
logS-4.43ADME Research, USCD
Caco2 permeability-4.37ADME Research, USCD
Predicted Properties
PropertyValueSource
Water Solubility0.00546 mg/mLALOGPS
logP3.58ALOGPS
logP4.15ChemAxon
logS-4.8ALOGPS
pKa (Strongest Acidic)18.92ChemAxon
pKa (Strongest Basic)-4.8ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area34.14 Å2ChemAxon
Rotatable Bond Count1ChemAxon
Refractivity92.71 m3·mol-1ChemAxon
Polarizability37.15 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Download (11.5 KB)
Spectra
Spectrum TypeDescriptionSplash Key
GC-MSGC-MS Spectrum - GC-MSsplash10-0fbc-5910000000-422e38df6de7e8b0a4b7View in MoNA
GC-MSGC-MS Spectrum - GC-MSsplash10-0fbc-5910000000-385f45345742235da8e0View in MoNA
LC-MS/MSLC-MS/MS Spectrum - Quattro_QQQ 10V, Positive (Annotated)splash10-014i-1009000000-0f8b7c3e6c2265c3889fView in MoNA
LC-MS/MSLC-MS/MS Spectrum - Quattro_QQQ 25V, Positive (Annotated)splash10-052b-8900000000-0b0167121b798e7e7534View in MoNA
LC-MS/MSLC-MS/MS Spectrum - Quattro_QQQ 40V, Positive (Annotated)splash10-052b-9400000000-881510cbcecd9cb61f4fView in MoNA
LC-MS/MSLC-MS/MS Spectrum - EI-B (JEOL JMS-01-SG-2) , Positivesplash10-024l-6923000000-639c7405f69825de7f90View in MoNA
LC-MS/MSLC-MS/MS Spectrum - EI-B (HITACHI M-52) , Positivesplash10-0229-2941000000-1e075d8489b79cf4e34aView in MoNA
MSMass Spectrum (Electron Ionization)splash10-006x-7931000000-f6ad83adccd7e016fa29View in MoNA
1D NMR1H NMR SpectrumNot Available
1D NMR1H NMR SpectrumNot Available
1D NMR13C NMR SpectrumNot Available
2D NMR[1H,13C] 2D NMR SpectrumNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as gluco/mineralocorticoids, progestogins and derivatives. These are steroids with a structure based on a hydroxylated prostane moiety.
KingdomOrganic compounds
Super ClassLipids and lipid-like molecules
ClassSteroids and steroid derivatives
Sub ClassPregnane steroids
Direct ParentGluco/mineralocorticoids, progestogins and derivatives
Alternative Parents
Substituents
  • Progestogin-skeleton
  • 20-oxosteroid
  • Oxosteroid
  • 3-oxosteroid
  • 3-oxo-delta-4-steroid
  • Delta-4-steroid
  • Cyclic ketone
  • Ketone
  • Hydrocarbon derivative
  • Organooxygen compound
  • Carbonyl group
  • Aliphatic homopolycyclic compound
Molecular FrameworkAliphatic homopolycyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Zinc ion binding
Specific Function:
The steroid hormones and their receptors are involved in the regulation of eukaryotic gene expression and affect cellular proliferation and differentiation in target tissues. Progesterone receptor isoform B (PRB) is involved activation of c-SRC/MAPK signaling on hormone stimulation.Isoform A: inactive in stimulating c-Src/MAPK signaling on hormone stimulation.Isoform 4: Increases mitochondrial ...
Gene Name:
PGR
Uniprot ID:
P06401
Molecular Weight:
98979.96 Da
References
  1. Madauss KP, Stewart EL, Williams SP: The evolution of progesterone receptor ligands. Med Res Rev. 2007 May;27(3):374-400. [PubMed:17013809 ]
  2. Gizard F, Robillard R, Gross B, Barbier O, Revillion F, Peyrat JP, Torpier G, Hum DW, Staels B: TReP-132 is a novel progesterone receptor coactivator required for the inhibition of breast cancer cell growth and enhancement of differentiation by progesterone. Mol Cell Biol. 2006 Oct;26(20):7632-44. [PubMed:17015480 ]
  3. Wu HB, Fabian S, Jenab S, Quinones-Jenab V: Progesterone receptors activation after acute cocaine administration. Brain Res. 2006 Dec 18;1126(1):188-92. Epub 2006 Nov 15. [PubMed:17109827 ]
  4. Boonyaratanakornkit V, McGowan E, Sherman L, Mancini MA, Cheskis BJ, Edwards DP: The role of extranuclear signaling actions of progesterone receptor in mediating progesterone regulation of gene expression and the cell cycle. Mol Endocrinol. 2007 Feb;21(2):359-75. Epub 2006 Nov 30. [PubMed:17138644 ]
  5. Tranguch S, Smith DF, Dey SK: Progesterone receptor requires a co-chaperone for signalling in uterine biology and implantation. Reprod Biomed Online. 2006 Nov;13(5):651-60. [PubMed:17169175 ]
  6. Luconi M, Bonaccorsi L, Maggi M, Pecchioli P, Krausz C, Forti G, Baldi E: Identification and characterization of functional nongenomic progesterone receptors on human sperm membrane. J Clin Endocrinol Metab. 1998 Mar;83(3):877-85. [PubMed:9506743 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Zinc ion binding
Specific Function:
Nuclear hormone receptor. The steroid hormones and their receptors are involved in the regulation of eukaryotic gene expression and affect cellular proliferation and differentiation in target tissues. Ligand-dependent nuclear transactivation involves either direct homodimer binding to a palindromic estrogen response element (ERE) sequence or association with other DNA-binding transcription fact...
Gene Name:
ESR1
Uniprot ID:
P03372
Molecular Weight:
66215.45 Da
References
  1. Kumar AS, Cureton E, Shim V, Sakata T, Moore DH, Benz CC, Esserman LJ, Hwang ES: Type and duration of exogenous hormone use affects breast cancer histology. Ann Surg Oncol. 2007 Feb;14(2):695-703. Epub 2006 Nov 14. [PubMed:17103262 ]
  2. Lessey BA, Palomino WA, Apparao KB, Young SL, Lininger RA: Estrogen receptor-alpha (ER-alpha) and defects in uterine receptivity in women. Reprod Biol Endocrinol. 2006;4 Suppl 1:S9. [PubMed:17118173 ]
  3. Yuri T, Tsukamoto R, Uehara N, Matsuoka Y, Tsubura A: Effects of different durations of estrogen and progesterone treatment on development of N-methyl-N-nitrosourea-induced mammary carcinomas in female Lewis rats. In Vivo. 2006 Nov-Dec;20(6B):829-36. [PubMed:17203775 ]
  4. Montero Girard G, Vanzulli SI, Cerliani JP, Bottino MC, Bolado J, Vela J, Becu-Villalobos D, Benavides F, Gutkind S, Patel V, Molinolo A, Lanari C: Association of estrogen receptor-alpha and progesterone receptor A expression with hormonal mammary carcinogenesis: role of the host microenvironment. Breast Cancer Res. 2007;9(2):R22. [PubMed:17341305 ]
  5. Ghebeh H, Tulbah A, Mohammed S, Elkum N, Bin Amer SM, Al-Tweigeri T, Dermime S: Expression of B7-H1 in breast cancer patients is strongly associated with high proliferative Ki-67-expressing tumor cells. Int J Cancer. 2007 Aug 15;121(4):751-8. [PubMed:17415709 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Zinc ion binding
Specific Function:
Receptor for both mineralocorticoids (MC) such as aldosterone and glucocorticoids (GC) such as corticosterone or cortisol. Binds to mineralocorticoid response elements (MRE) and transactivates target genes. The effect of MC is to increase ion and water transport and thus raise extracellular fluid volume and blood pressure and lower potassium levels.
Gene Name:
NR3C2
Uniprot ID:
P08235
Molecular Weight:
107066.575 Da
References
  1. Rupprecht R, Reul JM, van Steensel B, Spengler D, Soder M, Berning B, Holsboer F, Damm K: Pharmacological and functional characterization of human mineralocorticoid and glucocorticoid receptor ligands. Eur J Pharmacol. 1993 Oct 15;247(2):145-54. [PubMed:8282004 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid 17-alpha-monooxygenase activity
Specific Function:
Conversion of pregnenolone and progesterone to their 17-alpha-hydroxylated products and subsequently to dehydroepiandrosterone (DHEA) and androstenedione. Catalyzes both the 17-alpha-hydroxylation and the 17,20-lyase reaction. Involved in sexual development during fetal life and at puberty.
Gene Name:
CYP17A1
Uniprot ID:
P05093
Molecular Weight:
57369.995 Da
References
  1. Haidar S, Hartmann RW: C16 and C17 substituted derivatives of pregnenolone and progesterone as inhibitors of 17alpha-hydroxylase-C17, 20-lyase: synthesis and biological evaluation. Arch Pharm (Weinheim). 2002;335(11-12):526-34. [PubMed:12596217 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
activator
General Function:
Opioid receptor activity
Specific Function:
G-protein coupled opioid receptor that functions as receptor for endogenous alpha-neoendorphins and dynorphins, but has low affinity for beta-endorphins. Also functions as receptor for various synthetic opioids and for the psychoactive diterpene salvinorin A. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates th...
Gene Name:
OPRK1
Uniprot ID:
P41145
Molecular Weight:
42644.665 Da
References
  1. Dawson-Basoa ME, Gintzler AR: Estrogen and progesterone activate spinal kappa-opiate receptor analgesic mechanisms. Pain. 1996 Jan;64(1):169-77. [PubMed:8867260 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Molecular Weight:
55930.545 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Lin Y, Lu P, Tang C, Mei Q, Sandig G, Rodrigues AD, Rushmore TH, Shou M: Substrate inhibition kinetics for cytochrome P450-catalyzed reactions. Drug Metab Dispos. 2001 Apr;29(4 Pt 1):368-74. [PubMed:11259318 ]
  3. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitorinducer
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A5
Uniprot ID:
P20815
Molecular Weight:
57108.065 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A7
Uniprot ID:
P24462
Molecular Weight:
57525.03 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid 17-alpha-monooxygenase activity
Specific Function:
Conversion of pregnenolone and progesterone to their 17-alpha-hydroxylated products and subsequently to dehydroepiandrosterone (DHEA) and androstenedione. Catalyzes both the 17-alpha-hydroxylation and the 17,20-lyase reaction. Involved in sexual development during fetal life and at puberty.
Gene Name:
CYP17A1
Uniprot ID:
P05093
Molecular Weight:
57369.995 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d 24-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP1A1
Uniprot ID:
P04798
Molecular Weight:
58164.815 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, retinoid and xenobiotics. Preferentially oxidizes 17beta-estradiol to the carcinogenic 4-hydroxy derivative, and a variety of procarcinogenic compou...
Gene Name:
CYP1B1
Uniprot ID:
Q16678
Molecular Weight:
60845.33 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Exhibits a high coumarin 7-hydroxylase activity. Can act in the hydroxylation of the anti-cancer drugs cyclophosphamide and ifosphamide. Competent in the metabolic activation of aflatoxin B1. Constitutes the major nicotine C-oxidase. Acts as a 1,4-cineole 2-exo-monooxygenase. Possesses low phenacetin O-deethylation activity.
Gene Name:
CYP2A6
Uniprot ID:
P11509
Molecular Weight:
56501.005 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. In the epoxidation of arachidonic acid it generates only 14,15- and 11,12-cis-epoxyeicosatrienoic acids. It is the principal enzyme...
Gene Name:
CYP2C8
Uniprot ID:
P10632
Molecular Weight:
55824.275 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitorinducer
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Romiti N, Tramonti G, Chieli E: Influence of different chemicals on MDR-1 P-glycoprotein expression and activity in the HK-2 proximal tubular cell line. Toxicol Appl Pharmacol. 2002 Sep 1;183(2):83-91. [PubMed:12387747 ]
  2. Wang EJ, Casciano CN, Clement RP, Johnson WW: Active transport of fluorescent P-glycoprotein substrates: evaluation as markers and interaction with inhibitors. Biochem Biophys Res Commun. 2001 Nov 30;289(2):580-5. [PubMed:11716514 ]
  3. Leonessa F, Kim JH, Ghiorghis A, Kulawiec RJ, Hammer C, Talebian A, Clarke R: C-7 analogues of progesterone as potent inhibitors of the P-glycoprotein efflux pump. J Med Chem. 2002 Jan 17;45(2):390-8. [PubMed:11784143 ]
  4. Ueda K, Okamura N, Hirai M, Tanigawara Y, Saeki T, Kioka N, Komano T, Hori R: Human P-glycoprotein transports cortisol, aldosterone, and dexamethasone, but not progesterone. J Biol Chem. 1992 Dec 5;267(34):24248-52. [PubMed:1360010 ]
  5. Nagy H, Goda K, Fenyvesi F, Bacso Z, Szilasi M, Kappelmayer J, Lustyik G, Cianfriglia M, Szabo G Jr: Distinct groups of multidrug resistance modulating agents are distinguished by competition of P-glycoprotein-specific antibodies. Biochem Biophys Res Commun. 2004 Mar 19;315(4):942-9. [PubMed:14985103 ]
  6. Yamazaki M, Neway WE, Ohe T, Chen I, Rowe JF, Hochman JH, Chiba M, Lin JH: In vitro substrate identification studies for p-glycoprotein-mediated transport: species difference and predictability of in vivo results. J Pharmacol Exp Ther. 2001 Mar;296(3):723-35. [PubMed:11181899 ]
  7. Adachi Y, Suzuki H, Sugiyama Y: Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8. [PubMed:11785684 ]
  8. Borgnia MJ, Eytan GD, Assaraf YG: Competition of hydrophobic peptides, cytotoxic drugs, and chemosensitizers on a common P-glycoprotein pharmacophore as revealed by its ATPase activity. J Biol Chem. 1996 Feb 9;271(6):3163-71. [PubMed:8621716 ]
  9. Kim WY, Benet LZ: P-glycoprotein (P-gp/MDR1)-mediated efflux of sex-steroid hormones and modulation of P-gp expression in vitro. Pharm Res. 2004 Jul;21(7):1284-93. [PubMed:15290871 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Quaternary ammonium group transmembrane transporter activity
Specific Function:
Mediates tubular uptake of organic compounds from circulation. Mediates the influx of agmatine, dopamine, noradrenaline (norepinephrine), serotonin, choline, famotidine, ranitidine, histamin, creatinine, amantadine, memantine, acriflavine, 4-[4-(dimethylamino)-styryl]-N-methylpyridinium ASP, amiloride, metformin, N-1-methylnicotinamide (NMN), tetraethylammonium (TEA), 1-methyl-4-phenylpyridiniu...
Gene Name:
SLC22A2
Uniprot ID:
O15244
Molecular Weight:
62579.99 Da
References
  1. Hayer-Zillgen M, Bruss M, Bonisch H: Expression and pharmacological profile of the human organic cation transporters hOCT1, hOCT2 and hOCT3. Br J Pharmacol. 2002 Jul;136(6):829-36. [PubMed:12110607 ]
  2. Wu X, Kekuda R, Huang W, Fei YJ, Leibach FH, Chen J, Conway SJ, Ganapathy V: Identity of the organic cation transporter OCT3 as the extraneuronal monoamine transporter (uptake2) and evidence for the expression of the transporter in the brain. J Biol Chem. 1998 Dec 4;273(49):32776-86. [PubMed:9830022 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Secondary active organic cation transmembrane transporter activity
Specific Function:
Translocates a broad array of organic cations with various structures and molecular weights including the model compounds 1-methyl-4-phenylpyridinium (MPP), tetraethylammonium (TEA), N-1-methylnicotinamide (NMN), 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP), the endogenous compounds choline, guanidine, histamine, epinephrine, adrenaline, noradrenaline and dopamine, and the drugs quinine...
Gene Name:
SLC22A1
Uniprot ID:
O15245
Molecular Weight:
61153.345 Da
References
  1. Hayer-Zillgen M, Bruss M, Bonisch H: Expression and pharmacological profile of the human organic cation transporters hOCT1, hOCT2 and hOCT3. Br J Pharmacol. 2002 Jul;136(6):829-36. [PubMed:12110607 ]
  2. Wu X, Kekuda R, Huang W, Fei YJ, Leibach FH, Chen J, Conway SJ, Ganapathy V: Identity of the organic cation transporter OCT3 as the extraneuronal monoamine transporter (uptake2) and evidence for the expression of the transporter in the brain. J Biol Chem. 1998 Dec 4;273(49):32776-86. [PubMed:9830022 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Toxin transporter activity
Specific Function:
Mediates potential-dependent transport of a variety of organic cations. May play a significant role in the disposition of cationic neurotoxins and neurotransmitters in the brain.
Gene Name:
SLC22A3
Uniprot ID:
O75751
Molecular Weight:
61279.485 Da
References
  1. Hayer-Zillgen M, Bruss M, Bonisch H: Expression and pharmacological profile of the human organic cation transporters hOCT1, hOCT2 and hOCT3. Br J Pharmacol. 2002 Jul;136(6):829-36. [PubMed:12110607 ]
  2. Wu X, Kekuda R, Huang W, Fei YJ, Leibach FH, Chen J, Conway SJ, Ganapathy V: Identity of the organic cation transporter OCT3 as the extraneuronal monoamine transporter (uptake2) and evidence for the expression of the transporter in the brain. J Biol Chem. 1998 Dec 4;273(49):32776-86. [PubMed:9830022 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Transporter activity
Specific Function:
Involved in the ATP-dependent secretion of bile salts into the canaliculus of hepatocytes.
Gene Name:
ABCB11
Uniprot ID:
O95342
Molecular Weight:
146405.83 Da
References
  1. Wang EJ, Casciano CN, Clement RP, Johnson WW: Fluorescent substrates of sister-P-glycoprotein (BSEP) evaluated as markers of active transport and inhibition: evidence for contingent unequal binding sites. Pharm Res. 2003 Apr;20(4):537-44. [PubMed:12739759 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Transporter activity
Specific Function:
Mediates export of organic anions and drugs from the cytoplasm. Mediates ATP-dependent transport of glutathione and glutathione conjugates, leukotriene C4, estradiol-17-beta-o-glucuronide, methotrexate, antiviral drugs and other xenobiotics. Confers resistance to anticancer drugs. Hydrolyzes ATP with low efficiency.
Gene Name:
ABCC1
Uniprot ID:
P33527
Molecular Weight:
171589.5 Da
References
  1. Payen L, Delugin L, Courtois A, Trinquart Y, Guillouzo A, Fardel O: Reversal of MRP-mediated multidrug resistance in human lung cancer cells by the antiprogestatin drug RU486. Biochem Biophys Res Commun. 1999 May 19;258(3):513-8. [PubMed:10329417 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Virus receptor activity
Specific Function:
The hepatic sodium/bile acid uptake system exhibits broad substrate specificity and transports various non-bile acid organic compounds as well. It is strictly dependent on the extracellular presence of sodium.(Microbial infection) Acts as a receptor for hepatitis B virus.
Gene Name:
SLC10A1
Uniprot ID:
Q14973
Molecular Weight:
38118.64 Da
References
  1. Schroeder A, Eckhardt U, Stieger B, Tynes R, Schteingart CD, Hofmann AF, Meier PJ, Hagenbuch B: Substrate specificity of the rat liver Na(+)-bile salt cotransporter in Xenopus laevis oocytes and in CHO cells. Am J Physiol. 1998 Feb;274(2 Pt 1):G370-5. [PubMed:9486191 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on December 03, 2016 02:44